Vectorious Medical Technologies
Yovel Alush has a diverse work experience in the field of technology and automation. They started their career at Israeli Military Intelligence in 2015 as an Automation Engineer, specializing in test automation development for embedded applications. They have experience with various programming languages such as C#, Delphi, and Python, and are skilled in the operation of testing equipment.
In 2018, Yovel Alush advanced to the position of Automation Team Leader at Israeli Military Intelligence, leading a team in automation projects. They held this role until 2020.
In 2020, Yovel Alush joined Vectorious Medical Technologies as an Automation Engineer. Here, they were responsible for developing and upgrading a .Net automation framework and conducting data analysis using Python. They later transitioned to the role of DevOps Engineer, where they contributed to the DevOps team's work. Currently, Yovel Alush is serving as the DevOps Team Lead at Vectorious Medical Technologies.
Yovel Alush attended the Mosenson Elite Academy from 2014 to 2015, where they pursued practical engineering, focusing on electronic systems and computers. Then, from 2018 to 2022, Yovel Alush pursued an engineer's degree in electrical and electronics engineering at the Holon Institute of Technology.
This person is not in any teams
Vectorious Medical Technologies
1 followers
Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy.The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration.Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.